This week in drug discovery (30 Oct-3 Nov)  

News round-up for 30 October – 3 November by DDW Editor Reece Armstrong

My news highlights this week feature a variety of exciting clinical trial results and launches that are examining therapies for much-needed disease areas, new drug approvals and even a space mission with a pharma twist.

New UK therapy option for hard-to-treat lymphoma

The MHRA has granted conditional marketing authorisation for Abbvie’s Tepkinly (epcoritamab) as a bispecific treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

First spaceflight mission for drug development lab

Redwire will launch its in-space pharmaceutical manufacturing platform, PIL-BOX, onboard SpaceX’s 29th cargo resupply services mission (SpaceX-29) for NASA to the International Space Station (ISS).

Psychedelic depression drug trial shows rapid and robust response

Phase II interim data for psilocybin analogue CYB003 in major depressive disorder (MDD) showed rapid, robust, and clinically significant reduction of depression symptoms.

Chinese regulator approves complete HIV-1 injectable

The National Medical Products Administration (NMPA) of China has approved ViiV Healthcare’s Vocabria (cabotegravir injection) in combination with Janssen’s Rekambys (rilpivirine long-acting injection) for the treatment of HIV-1 infection.

First gene therapy trial for Hunter syndrome opens in Manchester, UK

UK regulatory authorities have approved the first trial of a gene therapy for young children with Hunter syndrome.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free